Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Niche-based screening identifies small-molecule inhibitors of leukemia stem cells.

Hartwell KA, Miller PG, Mukherjee S, Kahn AR, Stewart AL, Logan DJ, Negri JM, Duvet M, Järås M, Puram R, Dancik V, Al-Shahrour F, Kindler T, Tothova Z, Chattopadhyay S, Hasaka T, Narayan R, Dai M, Huang C, Shterental S, Chu LP, Haydu JE, Shieh JH, Steensma DP, Munoz B, Bittker JA, Shamji AF, Clemons PA, Tolliday NJ, Carpenter AE, Gilliland DG, Stern AM, Moore MAS, Scadden DT, Schreiber SL, Ebert BL, Golub TR.

Nat Chem Biol. 2013 Dec;9(12):840-848. doi: 10.1038/nchembio.1367. Epub 2013 Oct 27.

3.

Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications.

Dimitroulakos J, Ye LY, Benzaquen M, Moore MJ, Kamel-Reid S, Freedman MH, Yeger H, Penn LZ.

Clin Cancer Res. 2001 Jan;7(1):158-67.

4.

Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach.

Dimitroulakos J, Nohynek D, Backway KL, Hedley DW, Yeger H, Freedman MH, Minden MD, Penn LZ.

Blood. 1999 Feb 15;93(4):1308-18.

5.

A small molecule screening strategy with validation on human leukemia stem cells uncovers the therapeutic efficacy of kinetin riboside.

McDermott SP, Eppert K, Notta F, Isaac M, Datti A, Al-Awar R, Wrana J, Minden MD, Dick JE.

Blood. 2012 Feb 2;119(5):1200-7. doi: 10.1182/blood-2011-01-330019. Epub 2011 Dec 9.

6.

Proapoptotic and antitumor activities of the HMG-CoA reductase inhibitor, lovastatin, against Dalton's lymphoma ascites tumor in mice.

Ajith TA, Harikumar KB, Thasna H, Sabu MC, Babitha NV.

Clin Chim Acta. 2006 Apr;366(1-2):322-8. Epub 2005 Dec 27.

PMID:
16380106
7.

Novel synthetic inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase activity that inhibit tumor cell proliferation and are structurally unrelated to existing statins.

Perchellet JP, Perchellet EM, Crow KR, Buszek KR, Brown N, Ellappan S, Gao G, Luo D, Minatoya M, Lushington GH.

Int J Mol Med. 2009 Nov;24(5):633-43.

8.

Quantitative phenotyping-based in vivo chemical screening in a zebrafish model of leukemia stem cell xenotransplantation.

Zhang B, Shimada Y, Kuroyanagi J, Umemoto N, Nishimura Y, Tanaka T.

PLoS One. 2014 Jan 15;9(1):e85439. doi: 10.1371/journal.pone.0085439. eCollection 2014.

9.

Apomine enhances the antitumor effects of lovastatin on myeloma cells by down-regulating 3-hydroxy-3-methylglutaryl-coenzyme A reductase.

Roelofs AJ, Edwards CM, Russell RG, Ebetino FH, Rogers MJ, Hulley PA.

J Pharmacol Exp Ther. 2007 Jul;322(1):228-35. Epub 2007 Apr 5.

10.

Growth inhibition of neuroblastoma cells by lovastatin and L-ascorbic acid is based on different mechanisms.

Girgert R, Vogt Y, Becke D, Bruchelt G, Schweizer P.

Cancer Lett. 1999 Apr 1;137(2):167-72.

PMID:
10374838
11.

Targeting leukemia stem cells: in vitro veritas?

Bond HM, Mesuraca M, Morrone G.

Oncotarget. 2014 Feb 15;5(3):575-6. No abstract available.

12.

Histone deacetylase inhibitor treatment downregulates VLA-4 adhesion in hematopoietic stem cells and acute myeloid leukemia blast cells.

Mahlknecht U, Schönbein C.

Haematologica. 2008 Mar;93(3):443-6. doi: 10.3324/haematol.11796. Epub 2008 Feb 11.

13.

Niche displacement of human leukemic stem cells uniquely allows their competitive replacement with healthy HSPCs.

Boyd AL, Campbell CJ, Hopkins CI, Fiebig-Comyn A, Russell J, Ulemek J, Foley R, Leber B, Xenocostas A, Collins TJ, Bhatia M.

J Exp Med. 2014 Sep 22;211(10):1925-35. doi: 10.1084/jem.20140131. Epub 2014 Sep 1.

14.

A New Strategy to Target Acute Myeloid Leukemia Stem and Progenitor Cells Using Chidamide, a Histone Deacetylase Inhibitor.

Li Y, Chen K, Zhou Y, Xiao Y, Deng M, Jiang Z, Ye W, Wang X, Wei X, Li J, Liang J, Zheng Z, Yao Y, Wang W, Li P, Xu B.

Curr Cancer Drug Targets. 2015;15(6):493-503.

PMID:
26282548
15.

Role of Microenvironment in Resistance to Therapy in AML.

Tabe Y, Konopleva M.

Curr Hematol Malig Rep. 2015 Jun;10(2):96-103. doi: 10.1007/s11899-015-0253-6. Review.

16.

Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses.

Li HY, Appelbaum FR, Willman CL, Zager RA, Banker DE.

Blood. 2003 May 1;101(9):3628-34. Epub 2002 Dec 27.

17.

Selective induction of apoptosis by HMG-CoA reductase inhibitors in hepatoma cells and dependence on p53 expression.

Kah J, Wüstenberg A, Keller AD, Sirma H, Montalbano R, Ocker M, Volz T, Dandri M, Tiegs G, Sass G.

Oncol Rep. 2012 Sep;28(3):1077-83. doi: 10.3892/or.2012.1860. Epub 2012 Jun 12.

PMID:
22710979
18.

A screening-based approach to circumvent tumor microenvironment-driven intrinsic resistance to BCR-ABL+ inhibitors in Ph+ acute lymphoblastic leukemia.

Singh H, Shelat AA, Singh A, Boulos N, Williams RT, Guy RK.

J Biomol Screen. 2014 Jan;19(1):158-67. doi: 10.1177/1087057113501081. Epub 2013 Aug 29.

19.

Considerations for targeting malignant stem cells in leukemia.

Guzman ML, Jordan CT.

Cancer Control. 2004 Mar-Apr;11(2):97-104. Review.

20.

Selective activity of the histone deacetylase inhibitor AR-42 against leukemia stem cells: a novel potential strategy in acute myelogenous leukemia.

Guzman ML, Yang N, Sharma KK, Balys M, Corbett CA, Jordan CT, Becker MW, Steidl U, Abdel-Wahab O, Levine RL, Marcucci G, Roboz GJ, Hassane DC.

Mol Cancer Ther. 2014 Aug;13(8):1979-90. doi: 10.1158/1535-7163.MCT-13-0963. Epub 2014 Jun 16.

Supplemental Content

Support Center